Skip to content
Profile your compound using clinical endpoints

Explore Gubra’s
BLEO-IPF mouse models

Gubra offers advanced bleomycin-induced and spirometry-confirmed mouse models of Idiopathic Pulmonary Fibrosis (IPF). The combination of lung function and respiratory capacity testing and an automated AI-based histopathology pipeline enables objective and accurate analysis of drug effects.

 American Thoracic Society (ATS) 2024

Download our posters

Discover how we can advance your drug development with our preclinical bleomycin-induced mouse models with hallmarks of lung dysfunction confirmed using spirometry and whole body plethysmography.

Standard Study Outlines

We are experts in bridging preclinical and clinical development.

Vice President, Scientific Sales

Michael’s primary focus is on metabolic dysfunction-associated steatohepatitis (MASH), obesity and idiopathic pulmonary fibrosis (IPF). Michael help customers with his scientific expertise in metabolic and fibrotic diseases, and knowhow for the preclinical evaluation of drug candidates from discovery to IND-enabling.

Let’s meet at the EASL 2023

Contact us


Hørsholm Kongevej 11B
2970 Hørsholm

+45 3152 ­2650

Back To Top